CN101247818A - Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途 - Google Patents

Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途 Download PDF

Info

Publication number
CN101247818A
CN101247818A CNA2006800302306A CN200680030230A CN101247818A CN 101247818 A CN101247818 A CN 101247818A CN A2006800302306 A CNA2006800302306 A CN A2006800302306A CN 200680030230 A CN200680030230 A CN 200680030230A CN 101247818 A CN101247818 A CN 101247818A
Authority
CN
China
Prior art keywords
mas
antagonists
disorders
agonists
coupled receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800302306A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·苏扎道斯桑图斯
S·韦罗索布朗特皮恩黑罗
R·德法里亚厄希尔瓦
I·希尔瓦鲁拉
F·巴罗斯德苏萨
F·J·G·弗里扎德
A·M·道斯莱斯
L·R·德弗朗卡
A·J·费里拉
R·D·西尼斯特拉
M·J·卡姆帕格诺尔-桑图斯
W·N·德奥利维拉萨姆帕伊奥
M·德卡斯特罗利奥
L·卡佩斯贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Minas Gerais
Original Assignee
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Minas Gerais filed Critical Universidade Federal de Minas Gerais
Publication of CN101247818A publication Critical patent/CN101247818A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800302306A 2005-06-28 2006-06-28 Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途 Pending CN101247818A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0502497-8A BRPI0502497A (pt) 2005-06-28 2005-06-28 uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI05024978 2005-06-28

Publications (1)

Publication Number Publication Date
CN101247818A true CN101247818A (zh) 2008-08-20

Family

ID=37595483

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800302306A Pending CN101247818A (zh) 2005-06-28 2006-06-28 Mas g-蛋白偶联受体激动剂和拮抗剂作为凋亡活性调节剂用于预防和治疗疾病的用途

Country Status (7)

Country Link
US (1) US20080312129A1 (enExample)
EP (1) EP1904087A2 (enExample)
JP (3) JP2008546811A (enExample)
CN (1) CN101247818A (enExample)
BR (1) BRPI0502497A (enExample)
CA (1) CA2613126A1 (enExample)
WO (1) WO2007000036A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105873598A (zh) * 2013-07-03 2016-08-17 代表亚利桑那大学的亚利桑那校董会 用于治疗认知功能障碍的方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
US8653031B2 (en) * 2006-10-30 2014-02-18 Universidade Federal De Minas Gerais Process for the preparation of compositions of AT1 receptor antagonist and Angiotensin—(1-7)
WO2008089532A1 (en) * 2007-01-26 2008-07-31 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
BRPI0800585B8 (pt) 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
ES2393455T3 (es) 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
DE102009013456A1 (de) * 2009-03-18 2010-09-23 GÖPFERICH, Achim, Prof. Dr. Nanopartikel für die Erkennung von Zellen, durch Bindung an G-Protein gekoppelte Rezeptoren
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
KR20140140546A (ko) * 2012-02-10 2014-12-09 타릭스 파마슈티컬스 엘티디. 말초 혈관 질환의 치료를 위한 조성물 및 방법
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
AU2015294371B2 (en) 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
CN113207799B (zh) * 2021-03-19 2022-03-15 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法
EP4371556A1 (en) 2022-11-15 2024-05-22 Explicat Pharma GmbH Angiotensin(1-7) pharmaceutical compositions for inhalation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349530A (zh) * 1999-05-05 2002-05-15 阿文蒂斯药物德国有限公司 作为血管紧张肽(1－7)受体兴奋剂的1－(p－噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1599620A (zh) * 2001-11-05 2005-03-23 米纳斯吉拉斯联合大学 采用环糊精、脂质体和生物降解性聚合物和/或其混合物及其制品制备肽血管紧张素－(1－7 )和类似物、激动剂和拮抗剂制剂的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
EP1096957A1 (en) * 1998-06-18 2001-05-09 Johns Hopkins University School of Medicine Methods and reagents for intramuscular delivery of nucleic acids
US6236766B1 (en) * 1998-09-11 2001-05-22 General Electric Company Method and apparatus for zooming digital images
JP2002528390A (ja) * 1998-10-02 2002-09-03 セント エリザベス メディカル センター， インコーポレイテッド 細胞の生存を増強するためのａｋｔ組成物
AU1449500A (en) * 1998-10-22 2000-05-08 Curagen Corporation Genes and proteins predictive and therapeutic for renal disease and associated disorders
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
CA2373693A1 (en) * 1999-05-20 2000-11-30 Human Genome Sciences, Inc. Seven transmembrane receptor genes
WO2001073033A2 (en) * 2000-03-29 2001-10-04 Beth Israel Deaconess Medical Center, Inc. Anti-angiogenic and anti-tumor properties of matin and other laminin domains
JP2003532623A (ja) * 2000-06-30 2003-11-05 バイエル アクチェンゲゼルシャフト 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法
JP2004516036A (ja) * 2000-12-22 2004-06-03 アストラゼネカ・アクチエボラーグ Ｍａｓ受容体に結合するダイノルフィンａのアゴニストまたはアンタゴニストを分析する方法
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
WO2006005470A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
BRPI0503122A (pt) * 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349530A (zh) * 1999-05-05 2002-05-15 阿文蒂斯药物德国有限公司 作为血管紧张肽(1－7)受体兴奋剂的1－(p－噻吩基苄基)咪唑,其制备方法,其用途和含有它们的药物制剂
CN1599620A (zh) * 2001-11-05 2005-03-23 米纳斯吉拉斯联合大学 采用环糊精、脂质体和生物降解性聚合物和/或其混合物及其制品制备肽血管紧张素－(1－7 )和类似物、激动剂和拮抗剂制剂的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
余琴等: "心血管结构和功能增龄性变化的超声评价研究进", 《泸州医学院学报》 *
霍美蓉等: "药用辅料研究新进展--生物可降解聚合物", 《中国天然药物》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105873598A (zh) * 2013-07-03 2016-08-17 代表亚利桑那大学的亚利桑那校董会 用于治疗认知功能障碍的方法

Also Published As

Publication number Publication date
EP1904087A2 (en) 2008-04-02
WO2007000036A2 (en) 2007-01-04
BRPI0502497A (pt) 2007-02-06
JP2008546811A (ja) 2008-12-25
CA2613126A1 (en) 2007-01-04
US20080312129A1 (en) 2008-12-18
JP2013075911A (ja) 2013-04-25
JP2017114901A (ja) 2017-06-29
WO2007000036A3 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
JP2017114901A (ja) 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用
Senzaki et al. Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure
Paul et al. Physiology of local renin-angiotensin systems
Gutkowska et al. The role of oxytocin in cardiovascular regulation
US20170189489A1 (en) Cardiac muscle function and manipulation
He et al. Differential regulation of angiotensin II-induced expression of connective tissue growth factor by protein kinase C isoforms in the myocardium
Appelman-Dijkstra et al. Novel approaches to the treatment of osteoporosis
KR20080085201A (ko) 증가된 혈류에 의해 유발된 조직 손상의 치료법 또는예방법
CA2518550C (en) Cancer treatment using proanp peptides
Tuo et al. Lycorine inhibits Ang II-induced heart remodeling and inflammation by suppressing the PI3K-AKT/NF-κB pathway
Xiang et al. Cardiomyocyte-specific overexpression of human stem cell factor protects against myocardial ischemia and reperfusion injury
Jiang et al. Loss of USP22 alleviates cardiac hypertrophy induced by pressure overload through HiF1-α-TAK1 signaling pathway
Yu et al. Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression
Yao et al. Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction
AU2008309063B2 (en) Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1
Liu et al. Relaxin-2 prevents erectile dysfunction by cavernous nerve, endothelial and histopathological protection effects in rats with bilateral cavernous nerve injury
Vesely Cardiac and renal hormones: anticancer effects in vitro and in vivo
Hobara et al. Angiotensin II type 2 receptors facilitate reinnervation of phenol-lesioned vascular calcitonin gene-related peptide–containing nerves in rat mesenteric arteries
HK1124247A (en) Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
de Jonge et al. Controlling cardiomyocyte survival
Greenberg Cardiac remodeling
US20090214507A1 (en) Method of treating preventing, inhibiting or reducing damage to cardiac tissue
Yáñez Bisbe Role of TRPV4 channels in adverse cardiac remodelling
US20070191275A1 (en) Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments
CN108047315A (zh) 一类多肽药物Athycaltide及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124247

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124247

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080820